Profile of minocycline and its potential in the treatment of schizophrenia

Lulu Zhang,1,2 Jingping Zhao11Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, 2Department of Psychology, Guangzhou First People’s Hospital, Guangzhou, Guangdong, People&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang L, Zhao J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7710f8a052ef4016ab4a13e2053ddd4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7710f8a052ef4016ab4a13e2053ddd4a
record_format	dspace
spelling	oai:doaj.org-article:7710f8a052ef4016ab4a13e2053ddd4a2021-12-02T09:54:30ZProfile of minocycline and its potential in the treatment of schizophrenia1178-2021https://doaj.org/article/7710f8a052ef4016ab4a13e2053ddd4a2014-06-01T00:00:00Zhttp://www.dovepress.com/profile-of-minocycline-and-its-potential-in-the-treatment-of-schizophr-a17223https://doaj.org/toc/1178-2021 Lulu Zhang,1,2 Jingping Zhao11Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, 2Department of Psychology, Guangzhou First People’s Hospital, Guangzhou, Guangdong, People’s Republic of China Abstract: Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.Keywords: schizophrenia, minocycline, microglia, neuroinflammationZhang LZhao JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1103-1111 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhang L Zhao J Profile of minocycline and its potential in the treatment of schizophrenia
description	Lulu Zhang,1,2 Jingping Zhao11Mental Health Institute of the Second Xiangya Hospital, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, Changsha, Hunan, 2Department of Psychology, Guangzhou First People’s Hospital, Guangzhou, Guangdong, People’s Republic of China Abstract: Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.Keywords: schizophrenia, minocycline, microglia, neuroinflammation
format	article
author	Zhang L Zhao J
author_facet	Zhang L Zhao J
author_sort	Zhang L
title	Profile of minocycline and its potential in the treatment of schizophrenia
title_short	Profile of minocycline and its potential in the treatment of schizophrenia
title_full	Profile of minocycline and its potential in the treatment of schizophrenia
title_fullStr	Profile of minocycline and its potential in the treatment of schizophrenia
title_full_unstemmed	Profile of minocycline and its potential in the treatment of schizophrenia
title_sort	profile of minocycline and its potential in the treatment of schizophrenia
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/7710f8a052ef4016ab4a13e2053ddd4a
work_keys_str_mv	AT zhangl profileofminocyclineanditspotentialinthetreatmentofschizophrenia AT zhaoj profileofminocyclineanditspotentialinthetreatmentofschizophrenia
_version_	1718397952654835712

Profile of minocycline and its potential in the treatment of schizophrenia

Ejemplares similares